Brind.

Class Action Lawsuit Filed Against Cellebrite Following Financial Guidance Miss

1 report, 1 independent Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims on behalf of purchasers of Cellebrite DI Ltd. The investigation follows news that Cellebrite reported second-quarter 2026 financial results that missed its prior guidance for Annual Recurring Revenue.

From pr-inside.com

Why it matters

Some supportBrind's analysis of the reports

The lawsuit relates to financial disclosures made by Cellebrite, which had previously lowered its full-year ARR guidance and announced the replacement of CEO Thomas E. Hogan. Following these announcements, Cellebrite's stock price dropped 29.18% to $10.80 on August 13, 2026.

From pr-inside.com

Who's involved

  • CellebriteThe company subject to the investigation and class action claims.
  • Thomas E. HoganThe former CEO of Cellebrite, whose replacement was announced amid the financial issues.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • CellebriteSpeculative

    Investors in Cellebrite might face increased legal costs or changes in funding due to the class action investigation.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped